6740-85-8

Basic information

• Product Name: 2-Chlorophenyl cyclopentyl ketone
• Synonyms: 0-chlorphenylcyclopentylketone;Methanone, (2-chlorophenyl)cyclopentyl-;2-Chlorophenyl cyclopentyl;O-Chlorphenyl Cyclopentyl Ketone;(2-Chlorophenyl)-cyclopentylketone/2-ChlorophenylCyclopentanone/ O-Chlorphenyl Cyclopentyl Ketone/2-ChlorophenylCyclopentylKetone/ O-ChlorophenylCyclopentylKetone/(2-Chlorophenyl)cyclopentylketone ;2-CHLORPHENYL CYCLOPENTYL KETONE;o-Chlorphenyl cyclophentyl ketone;20Chlorophenylcyclopentylketone
• CAS NO: 6740-85-8
• Molecular Formula: C₁₂H₁₃ClO
• Molecular Weight: 208.68
• EINECS: 229-802-0
• Mol File: 6740-85-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 96
• Boiling Point: 96°C
• Flash Point: >100°C
• Appearance: liquid
• Density: 1.16
• Vapor Pressure: 0.00283mmHg at 25°C
• Refractive Index: 1.5470
• Storage Temp.: Refrigerator
• Solubility: Slightly miscible with chloroform and ethyl acetate.
• BRN: 1873022
• CAS DataBase Reference: 2-Chlorophenyl cyclopentyl ketone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chlorophenyl cyclopentyl ketone(6740-85-8)
• EPA Substance Registry System: 2-Chlorophenyl cyclopentyl ketone(6740-85-8)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 6740-85-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 6740-85-8 differently. You can refer to the following data:
1. 2-Chlorophenyl Cyclopentyl Ketone is used as a reagent in the preparation of bicyclic and polycyclic aromatic hydrocarbons.
2. 2-Chlorophenyl cyclopentyl ketone is used as a reagent in the preparation of bicyclic and polycyclic aromatic hydrocarbons. It acts as a pharmaceutical intermediate and also as an intermediate of ketamine.

InChI:InChI=1/C12H13ClO/c13-11-8-4-3-7-10(11)12(14)9-5-1-2-6-9/h3-4,7-9H,1-2,5-6H2

Upstream product

• 120-92-3 cyclopentanone 
• 17529-98-5 cyclopentanone p-tolylsulfonylhydrazone 
• 89-98-5 2-chloro-benzaldehyde 
• 3400-45-1 cyclopentanecarboxylic acid 
• 4524-93-0 Cyclopentanecarboxylic acid chloride 
• 1034156-02-9 o-chlorophenylmagnesium chloride 
• 609-65-4 o-chlorobenzoyl chloride 
• 142-29-0 cyclopentene 
• 873-32-5 2-Chlorobenzonitrile 
• 33240-34-5 cyclopentylmagnesium bromide 
• 19833-92-2 1-(2-chlorophenyl)(cyclopentyl)methanol 
• 137-43-9 Cyclopentyl bromide 
• 106961-63-1 (2-Chloro-phenyl)-(2-morpholin-4-yl-cyclopent-1-enyl)-methanone 
• 936-52-7 1-(N-morpholino)cyclopent-1-ene 

Downstream Products

• 79499-57-3 (±)-1-((2-chlorophenyl)(imino)methyl)cyclopentan-1-ol 
• 35211-10-0 norketamine 
• 100477-72-3 (S)-ketamine 
• 120199-64-6 2-Hydroxy-Norketamine 
• 33643-47-9 (-)-Ketamine hydrochloride 
• 83777-64-4 (R)-Norketamine 
• 83777-65-5 (S)-Norketamine 
• 19833-92-2 1-(2-chlorophenyl)(cyclopentyl)methanol 
• 6740-87-0 1-((2-chlorophenyl)(methylimino)methyl)cyclopentan-1-ol 
• 90717-17-2 (±)-(2-chlorophenyl)(1-hydroxycyclopentyl)methanone 
• 1867-66-9 (+/-)-ketamine hydrochloride 

Relevant articles and documents

Preparation method of high-purity esketamine hydrochloride ketone body

The invention discloses a preparation method of a high-purity esketamine hydrochloride ketone body. The structure of the esketamine hydrochloride ketone body is shown as a formula (I). The preparationmethod comprises the following steps of: by taking cyclopentanoic acid and o-chlorobromobenzene as starting materials, carrying out acylating chlorination reaction, metallization reaction and Grignard reaction to synthesize the esketamine hydrochloride ketone body. The esketamine hydrochloride ketone body obtained by the method has the characteristics of high purity, high yield, capability of being applied to preparation of esketamine hydrochloride bulk drugs and the like.

Process Research and Impurity Control Strategy of Esketamine

An improved synthesis of (S)-ketamine (esketamine) has been developed, which was cost-effective, and the undesired isomer could be recovered by racemization. Critical process parameters of each step were identified as well as the process-related impurities. The formation mechanisms and control strategies of most impurities were first discussed. Moreover, the (S)-ketamine tartrate is a dihydrate, which was disclosed for the first time. The practicable racemization catalyzed by aluminum chloride was carried out in quantitative yield with 99% purity. The ICH-grade quality (S)-ketamine hydrochloride was obtained in 51.1% overall yield (14.0% without racemization) by chiral resolution with three times recycling of the mother liquors. The robust process of esketamine could be industrially scalable.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.